問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Plastic Surgery

更新時間：2023-09-19

陳錫根
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳錫根

List

6Cases

2012-07-01 - 2020-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2015-01-01 - 2016-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Study ended1Sites

2019-08-01 - 2021-12-31

Phase III

BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

  • Condition/Disease

    Masseter Muscle Prominence

  • Test Drug

    BOTOX®

Participate Sites
4Sites

Terminated4Sites

2014-05-31 - 2017-12-31

Phase II

BOTOX® Treatment of Masseter Muscle Hypertrophy

  • Condition/Disease

    BOTOX® Treatment of Masseter Muscle Hypertrophy

  • Test Drug

    BOTOX

Participate Sites
4Sites

Terminated4Sites

2016-03-01 - 2016-08-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2017-01-01 - 2018-06-30

Phase III

A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of NEURONOX® vs. BOTOX® in Patients with Moderate to Severe Glabellar Lines

  • Condition/Disease

    Patients with moderate to severe glabellar lines

  • Test Drug

    Neuronox® Inj. (Clostridium Botulinum Toxin A)

Participate Sites
4Sites

Terminated4Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB